ArticleCancer management and research2018
Trends in incidence and mortality of female breast cancer during transition in Central China.
Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Temporal trends of breast cancer burden in the Western Pacific Region from 1990 to 2044: Implications from the Global Burden of Disease Study 2019.Journal of advanced research · 2024Article
- Depression, anxiety and stress among metastatic breast cancer patients on chemotherapy in China.BMC nursing · 2023Article
- The value of noncontrast MRI in evaluating breast imaging reporting and data system category 0 lesions on digital mammograms.Quantitative imaging in medicine and surgery · 2022Article
- Lifestyle and Socioeconomic Transition and Health Consequences of Breast Cancer in the East Asia Region, From 1990 to 2019.Frontiers in nutrition · 2022Article
- Mechanical loading attenuates breast cancer-associated bone metastasis in obese mice by regulating the bone marrow microenvironment.Journal of cellular physiology · 2021Article
- Time trends of major cancers incidence and mortality in Guangzhou, China 2004-2015: A Joinpoint and Age-Period-Cohort Analysis.Cancer medicine · 2021Article
- Epidemiological characteristics and forecasting incidence for patients with breast cancer in Shantou, Southern China: 2006-2017.Cancer medicine · 2021Article
- Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective.Breast cancer (Dove Medical Press) · 2021Review
- Trends and Projections in Breast Cancer Mortality among four Asian countries (1990-2017): Evidence from five Stochastic Mortality Models.Scientific reports · 2020Article
- Identification of FPR3 as a Unique Biomarker for Targeted Therapy in the Immune Microenvironment of Breast Cancer.Frontiers in pharmacology · 2020Article
- DCLK1 Plays a Metastatic-Promoting Role in Human Breast Cancer Cells.BioMed research international · 2019Article
- Recent insights into breast cancer incidence trends among four Asian countries using age-period-cohort model.Cancer management and research · 2019Article
- Screening of Prognostic Factors in Early-Onset Breast Cancer.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFollowing the implementation of breast cancer (BC) control strategies for years in Central China, the outcome needs to be evaluated and further strategies based on long-term surveillance should be formulated. Therefore, we examined the trends of BC incidence and mortality during 1990-2014 and projected them to 2024 in Wuhan, Central China. PATIENTS AND
methodsThe incidence and mortality data of BC were extracted from the Wuhan Cancer Registry. The average annual percentage changes (AAPCs) of the age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) were analyzed using Joinpoint regression. The Nordpred R-package was used to project BC incidence and mortality between 2015 and 2024. The age-period-cohort analysis was applied to evaluate the age, period, and cohort effects on the trends of BC incidence and mortality.
resultsOverall, the ASIR increased markedly from 20.01 to 44.26 per 100,000 (AAPC=3.3%, 95% CI: 1.7%, 5.0%) during 1990-2014, and it was projected to keep increasing in the next decade (AAPC=3.0%, 95% CI: 2.0%, 4.1%). The ASMR of BC leveled off during the study period (AAPC=0.4%, 95% CI: -0.2%, 0.9%). The BC mortality of the older group (aged 50-79 years) showed significant upward trends in both observed and projected periods. Strong age, period, and cohort effects were observed in BC incidence, and BC mortality was significantly driven by age and cohort effects.
conclusionThe ASIR in Wuhan was approaching those areas with the highest BC risk in China, and the evident increase in BC incidence suggested that prior strategies for BC control should be adopted. In particular, further strategies for reducing BC mortality in older age groups should be reinforced in Wuhan, Central China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.